Hiroyuki Murai

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis

Takaaki Ishizu, Manabu Osoegawa, Feng-Jun Mei et al. · Brain · 2005 · 331 citations · Full text

Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease

Yasumasa Ohyagi, Hideaki Asahara, De-Hua Chui et al. · The FASEB Journal · 2004 · 277 citations

Apoptosis, Cell Death, Social Sciences +18

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Srikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar et al. · Muscle & Nerve · 2019 · 239 citations · Full text